RT @AurelieRheumo: Orelabrutinib Brutonâs tyrosine kinase inhibitor in SLE RCT phase Ib/IIa SRI(4) wk 12 50mg 50% 8
Tweet Content
Orelabrutinib Bruton’s
tyrosine kinase inhibitor in SLE
RCT phase Ib/IIa
SRI(4) wk 12 50mg 50% 80mg 61% and 100mg 64% and 37.5% PBO
Trend ⬇️ proteinuria, anti-dsDNA & IgG
Safety: 3SAEs in OLE group
LB0005 @RheumNow #EULAR2022 https://t.co/4r16NTaZvT
Show on Archive Page
On
Display in Search Results
On
PDQ
Off